Immunic, Inc. (NASDAQ:IMUX) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Jessica Breu - Head, IR and Communications Daniel Vitt - CEO and President Glenn Whaley - CFO Andreas Muehler - Chief Medical Officer Conference Call Participants Andreas Argyrides - Wedbush Yasmeen Rahimi - Piper Sandler Matt Kaplan - Ladenburg Operator Jessica Breu Good morning, everyone, and welcome to Immunic's Third Quarter 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations ...

Immunic, Inc. (NASDAQ:IMUX) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Jessica Breu - Head, Investor Relations and Communications Daniel Vitt - Chief Executive Officer and President Glenn Whaley - Chief Financial Officer Hella Kohlhof - Chief Scientific Officer Conference Call Participants Andreas Argyrides - Wedbush Yasmeen Rahimi - Piper Sandler Matt Kaplan - Ladenburg Michael Kratky - SVB Securities Jessica Breu Good morning, everybody and welcome to ImmunicÂ's Second ...

lmmunic THERAPEUTICS Immunic Therapeutics Second Quarter 2022 Financial Results and Corporate Update NASDAQ: IMUX | August 4, 2022 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management' ...

IMMUNIC THERAPEUTICS Immunic Therapeutics First Quarter 2022 Financial Results and Corporate Update NASDAQ: IMUX | May 10, 2022 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management's i ...

Immunic Inc. (NASDAQ:IMUX) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Daniel Vitt – Chief Executive officer, President & Director Glenn Whaley – Vice President of Finance and Principal Financial & Accounting Officer Conference Call Participants Thomas Smith – SVB Leerink Yasmeen Rahimi – Piper Sandler Andreas Argyrides – Wedbush Matthew Kaplan – Lautenbach Tallmann Boobalan Pachaiyappan – H.C. Wainwright Zegbeh Jallah – Roth Capital Operator Good morning and welcome to Imm ...

Immunic inc. (NASDAQ:IMUX) Q4 2021 Earnings Conference Call February 24, 2021 8:00 AM ET Company Participants Daniel Vitt – Chief Executive officer, President & Director Glenn Whaley – VP of Finance and Principal Financial & Accounting Officer Andreas Muehler – Chief Medical Officer Conference Call Participants Jessica Vo – Piper Sandler Andreas Argyrides – Wedbush Gobind Singh – JMP Matt Kaplan – lender Zegbeh Jallah – Roth Capital Boobalan Pachaiyappan – H.C. Wainwright Matt Price – SVP Operator Good morn ...

Immunic THERAPEUTICS Immunic Therapeutics Fourth Quarter and Year-End 2021 Financial Results and Corporate Update NASDAQ: IMUX | February 24, 2022 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regar ...

Immunic, Inc. (NASDAQ:IMUX) Q3 Results Earnings Conference Call November 4, 2021 8:00 AM ET Company Participants Jessica Breu - Head of IR & Communications Daniel Vitt - CEO, President & Director Glenn Whaley - VP of Finance and Principal Financial & Accounting Officer Andreas Muehler - Chief Medical Officer Patrick Walsh - Chief Business Officer Inderpal Singh - General Counsel Conference Call Participants Yasmeen Rahimi - Piper Sandler Gobind Singh - JMP Securities Michael Kratky - SVB Leerink Matthew Kap ...

IMMUNIC THERAPEUTICS Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX | August 2021 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management's intentions, pl ...

| --- | --- | --- | --- | |-------|-------|-------|-------| | | | | | | | | | | | | | | | Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management's intentions, plans, beliefs, expectation ...